The trajectory of Sildenafil presents a complex picture for shareholders. While the initial introduction generated massive profits, the expiration of its exclusive rights opened the avenue to cheaper versions, https://thebookmarknight.com/story21608840/sildenafil-and-big-pharma-a-risky-opportunity